Connect with us

Technology

HealthVerity recognized in three 2023 Gartner® Hype Cycle™ reports

Published

on

Recognized for Life Science Clinical Development, Life Science Commercial Operations, and Healthcare Data, Analytics and AI 

PHILADELPHIA, Feb. 13, 2024 /PRNewswire/ — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced that it was recognized in three of the July 2023 Gartner Hype Cycles titled: Hype Cycle for Life Science Clinical Development, 2023, Hype Cycle for Life Science Commercial Operations, 2023, and Hype Cycle for Healthcare Data, Analytics and AI, 2023. This is the second year in a row that the company has been recognized in all three of these Hype Cycles and the third consecutive year for Life Science Commercial Operations.

HealthVerity was recognized as a vendor providing several different technology solutions in each of the three Hype Cycles:

Life Science Clinical DevelopmentPatient data tokenization – According to Gartner, “Patient data tokenization is the process by which clinical trial subjects/patients consent to have their anonymized health information linked to a subject identifier or token. The token can also be linked to existing real-world data (RWD) sources like healthcare claims and laboratory results. This enables life science companies to link patients who have consented to their retrospective RWD, following their activities prospectively for ongoing insights about branded treatments on patient health.” The Gartner report found that this technology is important because, “Patient data tokenization (PDT) enables patient data to be connected between different data sources, enabling life science companies to formulate a holistic, longitudinal view of the patient journey. RWD made available via tokenization can provide significant insight about patient health history, enabling insights about outcomes after a trial, intervention or treatment has been administered by a life science company.” 

RWD-based trials – “Real-world data (RWD)-based trials use RWD to optimize trial activities with applications that deliver improvements to patient recruitment and retention, protocol optimization, trial feasibility, and safety signal detection. As RWD becomes more available, life science companies and vendors are leveraging it to support effective protocol design, precision methods of finding subjects to successfully complete the trial, and improved data capture that leverages patient health records.”

Data monetization in HCLS – “Data monetization is a practice adopted by a healthcare and life science (HCLS) organization by which they make their proprietary data available to sell to external parties. The most mature examples are payers selling deidentified medical claims data to life science companies. This profile tracks monetization of new data types, utilizing new sharing mechanisms and vendors, targeted at new use cases, which are driving a new cycle of data monetization initiatives.” 

Life Science Commercial OperationsRWD curation and analytics platforms – According to Gartner, “This technology combines real-world data (RWD), such as electronic health records (EHR), medical and prescription claims, disease and patient registries, lab results, imaging and other sources, to provide a longitudinal view of a patient journey. The platform prepares data for delivery to downstream consumption platforms, applications and analytics. It automates the ingestion and linking of data from permissioned sources, manages identity, compliance and security.”

Healthcare Data, Analytics and AIData sharing in HCLS – “Data sharing in healthcare and life science (HCLS) reflects a broad range of use cases that knit together ecosystem partners to advance clinical care, research and discovery; improve public health; decrease health disparities; and lower costs. Data sharing in HCLS relies on a foundation of interoperability, privacy protecting policies and standards to enable the industry to safely and collaboratively drive new value streams through better data sharing partnerships.”

Data monetization in HCLS – Defined by Gartner as, “a practice adopted by a healthcare and life science (HCLS) organization by which they make their proprietary data available to sell to external parties. The most mature examples are payers selling deidentified medical claims data to life science companies. This profile tracks monetization of new data types, utilizing new sharing mechanisms and vendors, targeted at new use cases, which are driving a new cycle of data monetization initiatives.”

HealthVerity offers patient data tokenization services with HealthVerity Identity Manager, a leading patient matching and identity resolution technology that is 10x more accurate than legacy tokenization technologies. Identity Manager establishes a unique but persistent HealthVerity ID (HVID) to resolve patient identity over time and across data sources to create a fully interoperable single source of truth. HealthVerity FLOW is a middleware solution that can enable RWD-based clinical trials and be used as a RWD curation and analytics platform that leverages this source of truth capability to enable RWD-driven patient journey initiatives. For example, the platform can synchronize clinical trial participants, their permissions, and the broadest set of identifiable and de-identified data sources in a fully governed, HIPAA-compliant manner to accelerate the time to FDA submission. Additionally, HealthVerity offers data owners the ability to join the nation’s largest healthcare and consumer data ecosystem while managing all aspects of identity resolution, privacy protection and governance of data usage rights for the seamless exchange of unlimited real-world data on HealthVerity Marketplace.

“We are excited to be recognized by Gartner in the Hype Cycle reports,” said HealthVerity COO Andrew Goldberg. “We pride ourselves on offering the life sciences and healthcare sectors transformational technologies that synchronize unparalleled identity management with built-in privacy compliance and governance of data usage rights for the seamless exchange of a near limitless combination of healthcare and consumer data. We believe our inclusion in the Gartner Hype Cycle reports demonstrates the difference these solutions can have on advancing the science.”

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About HealthVerity
HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

HealthVerity Contact:
Colleen Stoker
614-738-0592
cstoker@healthverity.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthverity-recognized-in-three-2023-gartner-hype-cycle-reports-302059926.html

SOURCE HealthVerity

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Gold and Fractal EMS Announce a Partnership for an American BMS

Published

on

By

ANAHEIM, Calif., Sept. 17, 2024 /PRNewswire/ — Fractal EMS Inc. (“Fractal”), a leading provider of advanced solar and storage controls, has announced a groundbreaking partnership with Gold Electronic Equipment Inc. (“Gold”), a leading high-tech company specializing in R&D, active balancing technology and manufacturing of the battery management system (BMS). A signing ceremony and celebration was held on September 9th at the RE+ clean energy conference in Anaheim, California. The new partnership will provide a cybersecure American BMS to customers worldwide (“Fractal BMS”).

The Fractal BMS provides a 3-level BMS architecture (module, rack and system).  The design of the Fractal BMS has been finalized, featuring an American-sourced chip, printed circuit board assembly (PCBA), and cybersecurity, ensuring compliance with U.S. policies for sourcing and critical infrastructure protection. The Fractal BMS has the option to provide active cell balancing to maximize each battery cell’s useful capacity and life.

“Other companies proposing an American BMS have not addressed the cybersecurity concerns of the BMS. Some companies are licensing a foreign BMS or only providing a top-level device, neither of which cure cybersecurity threats and vulnerabilities. We are thrilled to collaborate with Gold to bring this advanced American BMS to the market. This partnership underscores our commitment to innovation, security, and supporting American technology,” said Daniel Crotzer, CEO at Fractal EMS.

Fractal BMS is scheduled for UL testing in late October 2024 and aims to become the gold standard for BESS deployments to mitigate risks associated with Foreign Entities of Concern (FEOC) and known cyber vulnerabilities in programmable devices. The American BMS will be available to battery manufacturers globally, offering a reliable and secure solution for battery management needs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gold-and-fractal-ems-announce-a-partnership-for-an-american-bms-302250726.html

SOURCE Fractal EMS Inc.

Continue Reading

Technology

Critical Intervention Services and S2 Institute Launch Free Crime Deterrence and Safety Training in Compliance with Florida Statute 768.0706(2)(c)

Published

on

By

Training Now Available On-Demand at www.HB837training.com

CLEARWATER, Fla., Sept. 17, 2024 /PRNewswire/ — Critical Intervention Services (CIS), in partnership with the S2 Institute, proudly announces the launch of a groundbreaking, on-demand Crime Deterrence and Safety Training program, available now at www.HB837training.com. This comprehensive training is free to the public until January 1, 2025, and is designed to help organizations comply with Florida Statute 768.0706(2)(c).

A major benefit for management companies: CIS clients who have undergone a Crime Prevention Through Environmental Design (CPTED) assessment will receive unlimited, no-cost access to this training for their employees — permanently. This unique offering ensures management companies can provide continuous safety training without incurring additional costs, enabling them to stay compliant with Florida Statute 768.0706(2)(c) and protect both current and future employees.

Comprehensive Crime Prevention Training

The training program, based on the proposed curriculum developed by the Florida Crime Prevention Training Institute (Department of Legal Affairs), covers critical strategies to prevent and respond to crime. Upon completion, participants will receive a certificate of completion, providing proof of their commitment to safety and preparedness.

CIS, known for its expertise in specialized security and safety solutions, including CPTED assessments, designed this program to deliver practical crime deterrence techniques that enhance safety and awareness across multifamily environments.

“We are excited to be the first to offer this crucial on-demand training, empowering both individuals and organizations to take proactive steps in improving their safety measures,” said Craig Gundry, Vice President of Special Projects at Critical Intervention Services. “With crime prevention more important than ever, we are committed to making this information easily accessible to everyone.”

Exclusive Features for Management Companies

For management companies, the training comes with enhanced benefits, including an online administrative portal for streamlined oversight. This portal allows management teams to monitor employee progress, ensuring full compliance with training requirements. Additionally, it provides on-demand access to training records, simplifying the retrieval of important documents as needed.

Through this administrative portal, management companies can enjoy complete transparency in tracking training progress, ensuring accountability and timely completion of required courses.

Enroll Today

The Crime Deterrence and Safety Training is available now at www.HB837training.com. Enrollment is open to all multifamily management companies, their employees, and the general public. Take advantage of this free offer before it expires on January 1, 2025.

About Critical Intervention Services (CIS)

Critical Intervention Services has performed more than 400 CPTED (Crime Prevention Through Environmental Design) assessments, positioning itself as a trusted leader in community safety evaluations. CIS has assessed more properties for compliance with Florida Statute 768.0706(2)(a) than any other provider. With the largest private sector team of Florida Crime Prevention Practitioners (FCPs), CIS provides timely and effective assessments to ensure properties meet the highest standards of crime prevention.

CIS serves clients across the residential, commercial, and government sectors, helping them mitigate security risks and enhance safety.

About S2 Institute

Founded in 1998, the S2 Safety & Intelligence Institute has trained thousands of professionals in security risk management and public safety. Over the past two decades, S2 has earned a global reputation as one of the premier sources for security and public safety training. In addition to public courses, S2 offers private training and consulting services to corporations and government organizations worldwide.

For Press Inquiries:
Craig Gundry, PSP, FCP
Vice President of Special Projects
Phone: 727-461-9417
Email: cgundry@cisworldservices.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/critical-intervention-services-and-s2-institute-launch-free-crime-deterrence-and-safety-training-in-compliance-with-florida-statute-768-07062c-302250729.html

SOURCE Critical Intervention Services

Continue Reading

Technology

Developmental & Epileptic Encephalopathy (DEE) Trials: Optimizing Endpoints, Determining MCID, and Enhancing Trial Data Quality, Upcoming Webinar Hosted by Xtalks

Published

on

By

In this free webinar, gain insights into the complex challenges of conducting clinical trials for developmental and epileptic encephalopathy. Attendees will learn about approaches for data collection across large geographic areas. The featured speaker will discuss the factors to consider when selecting cognitive and behavioral endpoints. The speaker will also share approaches for determining minimally clinically important difference.

TORONTO, Sept. 17, 2024 /PRNewswire-PRWeb/ — Clinical trials in patients with developmental and epileptic encephalopathy (DEE) present considerable challenges for research teams, including the difficulty in identifying patients, the large geographic spread of patients and the need for measurements that can catch even the smallest degree of change in behavior or function.

It becomes a near impossible task to find sites that are in the appropriate geographies and have the level of expertise to administer the scales necessary for signal detection.

One byproduct of these challenges is the difficulty that arises in site selection. It becomes a near impossible task to find sites that are in the appropriate geographies and have the level of expertise to administer the scales necessary for signal detection.

In this webinar, the expert speaker will address these obstacles and share solutions. She will describe approaches to collect data across large geographic areas and in locations that do not have specialized or experienced raters. She will share factors to consider when selecting cognitive and behavioral endpoints for DEE trials, including perspectives from regulatory agencies.

Moreover, she will describe the application of developmental assessments (e.g., Bayley-4) and behavioral scales (e.g., the Vineland-3), along with approaches for determining minimally clinically important difference (MCID) with these measures in DEE populations.

Register for this webinar to gain insights into the complex challenges of conducting clinical trials for developmental and epileptic encephalopathy.

Join Pamela Ventola, PhD, Chief Science Officer, Cogstate, for the live webinar on Thursday, October 3, 2024, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Developmental & Epileptic Encephalopathy (DEE) Trials: Optimizing Endpoints, Determining MCID, and Enhancing Trial Data Quality.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/developmental–epileptic-encephalopathy-dee-trials-optimizing-endpoints-determining-mcid-and-enhancing-trial-data-quality-upcoming-webinar-hosted-by-xtalks-302250641.html

SOURCE Xtalks

Continue Reading

Trending